Inhibikase Therapeutics, Inc. (IKT) Debt Components
- 2025-12-31: Long-term Debt and Lease Obligation, CurrentUSD $0.00; Notes PayableUSD (m); Notes Payable, CurrentUSD (m); Long-term DebtUSD (m).
- 2025-09-30: Long-term Debt and Lease Obligation, CurrentUSD $0.00; Notes PayableUSD (m); Notes Payable, CurrentUSD (m); Long-term DebtUSD (m).
- 2025-06-30: Long-term Debt and Lease Obligation, CurrentUSD $37.94K; Notes PayableUSD (m); Notes Payable, CurrentUSD (m); Long-term DebtUSD (m).
- 2025-03-31: Long-term Debt and Lease Obligation, CurrentUSD $74.77K; Notes PayableUSD (m); Notes Payable, CurrentUSD (m); Long-term DebtUSD (m).
Inhibikase Therapeutics, Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt and Lease Obligation, Current USD | Notes Payable USD | Notes Payable, Current USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Debt Instrument, Interest Rate, Stated Percentage pure | Debt Instrument, Convertible, Threshold Consecutive Trading Days Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $37.94K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $74.77K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $110.52K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $145.21K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $152.22K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $151.16K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $150.09K | $381.78K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | (m) | $381.78K | $381.78K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $149.03K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $147.97K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $146.90K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-01-24 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1 month · 10.00 |
| 2022-12-31 | $145.84K | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $142.05K | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $248.91K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $248.91K | (m) | $248.91K | $248.91K | $0.00 | $0.00 | $0.00 | $0.00 | (m) | (m) | (m) |
| 2021-09-30 | (m) | $248.91K | $248.91K | $248.91K | $248.91K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $248.91K | (m) | $248.91K | $248.91K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $1.24M | $994.79K | $1.24M | $248.91K | (m) | (m) | (m) | (m) | $994.79K | (m) | (m) |
| 2020-12-31 | (m) | $319.00K | $42.53K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-02-05 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1.59% | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |